MYOV - Myovant Sciences Ltd.

NYSE - NYSE Delayed Price. Currency in USD
22.97
+0.46 (+2.04%)
At close: 4:01PM EDT

22.73 -0.24 (-1.05%)
After hours: 4:26PM EDT

Stock chart is not supported by your current browser
Previous Close22.51
Open22.86
Bid22.82 x 800
Ask23.00 x 800
Day's Range22.37 - 23.08
52 Week Range14.32 - 27.45
Volume34,597
Avg. Volume64,005
Market Cap1.627B
Beta (3Y Monthly)0.77
PE Ratio (TTM)N/A
EPS (TTM)-3.84
Earnings DateJun 5, 2019 - Jun 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.60
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    Myovant Sciences to Present at Upcoming Investor Conferences

    BASEL, Switzerland , March 5, 2019 /PRNewswire/ -- Myovant Sciences (NYSE:  MYOV ), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced ...

  • MoneyShow27 days ago

    Myovant- "Value Creation" in Cancer Treatment

    In our view, Myovant (MYOV) is poised for significant value creation in the next 6-12 months, explains John McCamant, biotechnology specialist and editor of The Medical Technology Stock Letter.

  • Motley Foollast month

    4 Disruptive Healthcare Stocks You've Never Heard Of

    Do these under-the-radar stocks deserve a spot in your growth stock portfolio?

  • Associated Presslast month

    Myovant Sciences: Fiscal 3Q Earnings Snapshot

    The Hamilton, Bermuda-based company said it had a loss of $1.04 per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • PR Newswirelast month

    Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018

    - Top-line results for LIBERTY 1 and LIBERTY 2 Phase 3 trials in uterine fibroids as well as HERO Phase 3 trial in prostate cancer expected in Q2, Q3 and Q4 2019, respectively - BASEL, Switzerland , Feb. ...

  • Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences
    GuruFocus.com2 months ago

    Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences

    Former tiger cub keeps investing in biotech companies

  • PR Newswire2 months ago

    Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

    - In addition to Roivant, four Vants will be presenting at JPM this year NEW YORK and BASEL, Switzerland , Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy , Founder and ...

  • PR Newswire3 months ago

    Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

    BASEL, Switzerland, Dec. 20, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.

  • PR Newswire4 months ago

    Myovant Sciences to Participate in Two Upcoming Investor Conferences

    Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.

  • GlobeNewswire4 months ago

    Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire4 months ago

    Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018

    - Completed Patient Enrollment in Phase 3 LIBERTY 1 and HERO Trials - - Completed Screening in Phase 3 LIBERTY 2 Trial - - On Track to Announce Top-line Results from All Five Relugolix Phase 3 Clinical ...

  • PR Newswire4 months ago

    Myovant Strengthens Management Team and Adds New Directors to the Board

    - Kim Sablich, Chief Commercial Officer, and Jeff Nornhold, Senior Vice President, Pharmaceutical Operations & Development, join Myovant's Executive Committee - Myrtle Potter, Mark Guinan and Frank Torti, ...

  • PR Newswire5 months ago

    Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer

    - Top-line data expected in fourth quarter of 2019 BASEL, Switzerland , Oct. 24, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced it has completed patient enrollment in its pivotal Phase ...

  • PR Newswire5 months ago

    Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress

    BASEL, Switzerland, Oct. 10, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a Phase 1 trial of MVT-602, a novel kisspeptin-1 receptor agonist in development as a potential treatment for female infertility in women as part of assisted reproduction, such as in vitro fertilization (IVF). Results of the study showed that administration of MVT-602 in healthy premenopausal women in the follicular phase produced a dose-related increase in luteinizing hormone concentrations and expected effects on follicle-stimulating hormone and estradiol.

  • Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
    PR Newswire5 months ago

    Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding

    BASEL, Switzerland and REDWOOD CITY, Calif., Oct. 8, 2018 /PRNewswire/ -- Myovant Sciences (MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, and Flo Health, a company developing the world's fastest growing artificial intelligence (AI)-driven platform for women's health with 22 million active users, announced today a partnership to create a digital tool to screen for heavy menstrual bleeding. Affecting more than 25 percent of women, heavy menstrual bleeding is associated with diseases such as uterine fibroids and can negatively impact a woman's quality of life.

  • PR Newswire7 months ago

    Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018

    - Completed patient screening for Phase 3 LIBERTY 1 Trial - - On track to announce top-line results from all relugolix Phase 3 clinical trials during 2019 - - Ended first fiscal quarter of 2018 with $235.6 ...

  • PR Newswire8 months ago

    Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares

    BASEL, Switzerland, July 12, 2018 /PRNewswire/ -- Myovant Sciences Ltd. (MYOV) ("Myovant"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases today announced the pricing of its underwritten public offering of 3,333,334 of its common shares at a price to the public of $22.50 per share. Gross proceeds to Myovant from the offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  All of the common shares are being offered by Myovant. In connection with this offering, Myovant has granted the underwriters a 30-day option to purchase up to an additional 500,000 of its common shares on the same terms and conditions.  The offering is expected to close on July 17, 2018, subject to customary closing conditions.  Myovant currently intends to use the net proceeds from the offering primarily to fund its clinical development programs, preparations for the potential commercial launch of relugolix, as well as for working capital and other general corporate purposes.

  • PR Newswire8 months ago

    Myovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares

    BASEL, Switzerland, July 11, 2018 /PRNewswire/ -- Myovant Sciences Ltd. (MYOV) ("Myovant"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases today announced that it has commenced an underwritten public offering of $75 million of its common shares. All of the common shares are being offered by Myovant. In connection with this offering, Myovant expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares in the offering on the same terms and conditions.

  • PR Newswire8 months ago

    Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids

    BASEL, Switzerland, July 10, 2018 /PRNewswire/ -- Myovant Sciences (NYSE:  MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that it has completed screening patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating relugolix in women with heavy menstrual bleeding associated with uterine fibroids. Uterine fibroids are debilitating and result in heavy menstrual bleeding in millions of women throughout the world, often requiring a hysterectomy.

  • ACCESSWIRE9 months ago

    Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma

    LONDON, UK / ACCESSWIRE / June 21, 2018 / If you want access to our free research report on Biohaven Pharma Holding Co. Ltd (BHVN) ("Biohaven"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BHVN as the Company's latest news hit the wire. On June 19, 2018, the Company announced that it has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000), or BHV-3500, and certain derivative compounds thereof to Royalty Pharma for $100 million. Active-Investors.com is currently working on the research report for Myovant Sciences Ltd (MYOV), which also belongs to the Healthcare sector as the Company Biohaven Pharma Holding.

  • PR Newswire9 months ago

    Myovant Sciences to Present at First Annual Roivant Pipeline Day

    BASEL, Switzerland, June 18, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the first annual Roivant Pipeline Day on July 10, 2018 at 2:30 p.m. ET. A live webcast will be available via the Events page under the Investors and Media section of Myovant's website at www.myovant.com. Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.

  • Myovant Sciences Ltd (NYSE:MYOV): Earnings Expected To Remain Subdued
    Simply Wall St.9 months ago

    Myovant Sciences Ltd (NYSE:MYOV): Earnings Expected To Remain Subdued

    In March 2018, Myovant Sciences Ltd (NYSE:MYOV) announced its most recent earnings update, which revealed company earnings became less negative compared to the previous year’s level – great news forRead More...

  • PR Newswire9 months ago

    Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018

    - On track for top-line results from all relugolix Phase 3 clinical studies during 2019 - Ended Fiscal Year 2017 with $200.6 million in cash and committed financings - Raised approximately $80.1 million ...